Pulmonary toxicity associated with pomalidomide

Gajić, Snežana; Callahan, Elliott C.; Brown, James K.; Elicker, Brett M.; Ley, Brett; Blanc, Paul D.

doi:10.5588/ijtld.18.0244

Cited by 5 publications

(9 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The histological and radiological patterns vary, including organizing/hypersensitivity/(non-specific) interstitial pneumonitis, acute respiratory distress syndrome, and diffuse alveolar haemorrhage. Four prior acute lung toxicity reports exist related to pomalidomide [12][13][14]. It usually takes 8 -120 days from initiation of treatment to onset of symptoms.…”

Section: Pneumonia 13% 11%mentioning

confidence: 99%

“…Pulmonary toxicity associated with elotuzumab (combined with lenalidomide/pomalidomide and dexamethasone) was barely described in Phase 1-3 clinical trials [5][6][7]. Only one case report of elotuzumab induced interstitial lung disease exists [8], with a few cases reports on lenalidomide and pomalidomide induced interstitial lung disease [9][10][11][12][13][14]. This article covers two cases of acute hypoxic respiratory failure upon administration of elotuzumab, and both treated successfully with corticosteroids.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

A Review of Interstitial Pneumonitis Caused by Elotuzumab Through Case Discussions and Academic Writings

Ghous

Shoukat

Tarar

et al. 2020

Cureus

View full text Add to dashboard Cite

Patients with relapsed or refractory multiple myeloma have undergone two or three previous therapies are now being treated with a humanized IgG1 monoclonal antibody elotuzumab (HuLuc63) that targets F7 signalling lymphocytic activation molecule F7 (SLAMF7)-a signalling lymphocytic activation molecule. It is combined with dexamethasone and lenalidomide/pomalidomide for therapy. Adverse effects associated with elotuzumab consists of peripheral neuropathy, fever, constitutional symptoms (fatigue, headache, decreased appetite), and infections. A rare side effect of interstitial lung disease has only been observed in a single case. There are two case studies presented below of hypoxic respiratory failure upon this monoclonal antibody treatment both were successfully treated with steroid therapy. This article brings forth the hypothesis that elotuzumab can cause pneumonitis, and discontinuation of elotuzumab along with highdose corticosteroids helps reverse the pneumonitis.

show abstract

Section: Pneumonia 13% 11%mentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

A Review of Interstitial Pneumonitis Caused by Elotuzumab Through Case Discussions and Academic Writings

Ghous

Shoukat

Tarar

et al. 2020

Cureus

View full text Add to dashboard Cite

show abstract

“…Рекомендовано немедленно приостановить распространение и отозвать с рынка даклизумаб. Специалистам здравоохранения следует связаться с пациентами, принимающими даклизумаб, отменить препарат и предложить альтернативное лечение 3 .…”

Section: инновационные лекарственные препаратыunclassified

“…В марте 2018 г. FDA на основании результатов пострегистрационных исследований [3] приняло решение о дополнении инструкций по медицинскому применению ЛС, содержащих помалидомид, информацией о риске развития DRESS синдрома, синдрома Стивенса-Джонсона и синдрома Лайелла, а также интерстициального поражения легких 5 .…”

Section: инновационные лекарственные препаратыunclassified

“…Синдром Стивенса-Джонсона и токсический эпидермальный некролиз (синдром Лайелла) -тяжелые системные аллергические реакции замедленного типа, варианты единого патологического процесса, протекающего с эрозивным поражением слизистых оболочек и распространенными кожными DRESS синдром -это реакция гиперчувствительности на ЛС, сопровождающаяся лихорадкой, кожной сыпью, лимфаденопатией, эозинофилией, поражением внутренних органов (гепатит, интерстициальная нефропатия и интерстициальное заболевание легких), которая развивается в течение 2-6 недель после начала применения препарата [3].…”

Section: инновационные лекарственные препаратыunclassified

See 1 more Smart Citation

The Adverse Drug Reactions Registered During the Postmarketing Period

Шубникова¹,

Дармостукова²,

Букатина³

et al. 2019

Bezopasnost' i risk farmakoterapii

View full text Add to dashboard Cite

Efficacy, safety and biotransformation features of any drug are fully revealed during widely using. Therefore, postmarketing studies of the pharmacological properties of drugs are an integral component of pharmacovigilance. The aim of this study was to evaluate the nature and frequency of drugs adverse reactions that have been reported in the post-marketing period, as well as a review of measures taken by foreign regulatory authorities to ensure the safety of use of these drugs. The results of monitoring the drug safety in the post-marketing period used in clinical practice during various time intervals are presented: from several years (atelizumab, daclizumab) to several decades (valproate, retinoids). The review included data from decisions of regulatory authorities, published in 2018. Recommendations from foreign sources on the rational use of drugs, ways to increase the benefit/risk ratio of adverse reactions when using drugs from different therapeutic groups and/or the need for changes in the instructions on their medical use due to changes in the safety profile are considered. These recommendations will be helpful to healthcare professionals, as well as persons authorized for pharmacovigilance by pharmaceutical companies. Particularly, this information may be of interest to rheumatologists, oncologists, neurologists, psychiatrists, as well as other physicians who use atezolizumab, tocilisumab, daclizumab, pomalidomide, valproate sodium and valproic acid, retinoids, clarithromycin, cotrimaxozol, cefalexine, hydroxycarbamide, ritonavir.

show abstract

Pomalidomide

2018

Reactions Weekly

View full text Add to dashboard Cite

Pulmonary toxicity associated with pomalidomide

Cited by 5 publications

References 0 publications

A Review of Interstitial Pneumonitis Caused by Elotuzumab Through Case Discussions and Academic Writings

A Review of Interstitial Pneumonitis Caused by Elotuzumab Through Case Discussions and Academic Writings

The Adverse Drug Reactions Registered During the Postmarketing Period

Pomalidomide

Contact Info

Product

Resources

About